| Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 100.50 mm | 100.50 mm | 100.50 mm | 100.50 mm | 100.50 mm | 100.50 mm |
| Cash burn (monthly) | (no burn) | 18.06 mm | 19.40 mm | 20.86 mm | 28.03 mm | 21.61 mm |
| Cash used (since last report) | n/a | 27.70 mm | 29.76 mm | 32.00 mm | 43.01 mm | 33.15 mm |
| Cash remaining | n/a | 72.80 mm | 70.74 mm | 68.50 mm | 57.49 mm | 67.35 mm |
| Runway (months of cash) | n/a | 4.0 | 3.6 | 3.3 | 2.1 | 3.1 |
| 13F holders | Current |
|---|---|
| Total holders | 210 |
| Opened positions | 29 |
| Closed positions | 28 |
| Increased positions | 71 |
| Reduced positions | 64 |
| 13F shares | Current |
|---|---|
| Total value | 1.64 tn |
| Total shares | 75.54 mm |
| Total puts | 284.00 k |
| Total calls | 220.30 k |
| Total put/call ratio | 1.3 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 7.01 mm | $172.56 bn |
| EcoR1 Capital | 6.73 mm | $165.67 bn |
| BlackRock | 6.50 mm | $160.00 bn |
| T. Rowe Price | 3.85 mm | $94.92 mm |
| PFE Pfizer | 3.46 mm | $326.63 mm |
| FMR | 2.88 mm | $71.02 bn |
| RTW Investments | 2.78 mm | $68.53 bn |
| Citadel Advisors | 2.71 mm | $66.69 bn |
| BLVGF Bellevue | 2.39 mm | $58.78 bn |
| Paradigm Biocapital Advisors | 2.34 mm | $57.63 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 24 Jun 24 | Saik Andrew | Common Stock | Grant | Acquire A | No | No | 0 | 61,409 | 0.00 | 61,409 |
| 24 Jun 24 | Saik Andrew | Stock Option Common Stock | Grant | Acquire A | No | No | 24.97 | 94,418 | 2.36 mm | 94,418 |
| 17 Jun 24 | Angela M Cacace | Common Stock | Grant | Acquire A | No | No | 0 | 15,995 | 0.00 | 51,852 |
| 17 Jun 24 | Angela M Cacace | Stock Option Common Stock | Grant | Acquire A | No | No | 24.94 | 24,632 | 614.32 k | 24,632 |
| 29 May 24 | Norwalk Leslie V | Common Stock | Grant | Acquire A | No | No | 0 | 5,899 | 0.00 | 10,020 |
| 29 May 24 | Norwalk Leslie V | Stock Option Common Stock | Grant | Acquire A | No | No | 33.9 | 9,070 | 307.47 k | 9,070 |
